摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3,5-bis(4-methoxyphenyl)-2-((E)-3-(4-methoxyphenyl)acryloyl)-4-nitrocyclohexanone | 1313195-54-8

中文名称
——
中文别名
——
英文名称
3,5-bis(4-methoxyphenyl)-2-((E)-3-(4-methoxyphenyl)acryloyl)-4-nitrocyclohexanone
英文别名
3,5-bis(4-methoxyphenyl)-2-[(E)-3-(4-methoxyphenyl)prop-2-enoyl]-4-nitrocyclohexan-1-one
3,5-bis(4-methoxyphenyl)-2-((E)-3-(4-methoxyphenyl)acryloyl)-4-nitrocyclohexanone化学式
CAS
1313195-54-8
化学式
C30H29NO7
mdl
——
分子量
515.563
InChiKey
UDHKYSBNKLLYCZ-UBKPWBPPSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5
  • 重原子数:
    38
  • 可旋转键数:
    8
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.27
  • 拓扑面积:
    108
  • 氢给体数:
    0
  • 氢受体数:
    7

反应信息

  • 作为产物:
    描述:
    1-(4-甲氧苯基)-2-硝基乙烯(1E,6E)-1,7-bis(4-methoxyphenyl)hepta-1,6-diene-3,5-dione 在 C27H31N5O3S 作用下, 以 四氢呋喃 为溶剂, 反应 72.0h, 生成 3,5-bis(4-methoxyphenyl)-2-((E)-3-(4-methoxyphenyl)acryloyl)-4-nitrocyclohexanone 、 3,5-bis(4-methoxyphenyl)-2-((E)-3-(4-methoxyphenyl)acryloyl)-4-nitrocyclohexanone 、 3,5-bis(4-methoxyphenyl)-2-((E)-3-(4-methoxyphenyl)acryloyl)-4-nitrocyclohexanone
    参考文献:
    名称:
    Diastereo- and enantioselective synthesis of densely functionalized cyclohexanones via double Michael addition of curcumins with nitroalkenes
    摘要:
    The asymmetric double Michael additions of curcumins to nitroalkenes to afford highly functionalized cyclohexanones have been carried out for the first time. A combination of a dihydrocinchonine-thiourea organocatalyst and K2CO3 was found to be the most effective in obtaining the desired cyclohexanones in good yield, diastereoselectivity and enantioselectivity. (C) 2012 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.tetasy.2012.04.011
点击查看最新优质反应信息

文献信息

  • CURCUMIN DERIVATIVES
    申请人:Namboothiri Irishi N.N.
    公开号:US20110160276A1
    公开(公告)日:2011-06-30
    A compound has Formula VIII where, X is —C(O)R, —C(O)OR, —CN, —NO 2 , —S(O) 2 R′, —P(O)(OR) 2 ; each R is individually H, alkyl, or alkenyl; R′ is alkyl or akenyl; R 1 is aryl, alkenyl, arylalkenyl, heterocyclyl, or heteroaryl; and R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are individually H, alkoxy, or hydroxy. In some cases, X is NO 2 . Pharmaceutical compositions of the compound of Formula VIII with a pharmaceutically acceptable carrier may be prepared. The compounds may be used for inhibition of cyclooxygenase-2.
    该化合物的化学式为VIII,其中X为—C(O)R、—C(O)OR、—CN、—NO2、—S(O)2R′、—P(O)(OR)2;每个R分别为H、烷基或烯基;R′为烷基或烯基;R1为芳基、烯基、芳基烯基、杂环烷基或杂环芳基;R2、R3、R4、R5、R6、R7、R8、R9、R10和R11分别为H、烷氧基或羟基。在某些情况下,X为NO2。可以制备该化合物的药物组合物,与药物可接受载体混合。该化合物可用于抑制环氧化酶-2。
  • US8410177B2
    申请人:——
    公开号:US8410177B2
    公开(公告)日:2013-04-02
  • [EN] CURCUMIN DERIVATIVES<br/>[FR] DÉRIVÉS DE CURCUMINE
    申请人:INDIAN INST TECHNOLOGY BOMBAY
    公开号:WO2011080550A1
    公开(公告)日:2011-07-07
    A compound has Formula VIII where, X is -C(O)R, -C(O)OR, -CN, -NO2, -S(O)2R', -P(O)(OR)2; each R is individually H, alkyl, or alkenyl; R' is alkyl or akenyl; R1 is aryl, alkenyl, arylalkenyl, heterocyclyl, or heteroaryl; and R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11 are individually H, alkoxy, or hydroxy. In some cases, X is NO2. Pharmaceutical compositions of the compound of Formula (VIII) with a pharmaceutically acceptable carrier may be prepared. The compounds may be used for inhibition of cyclooxygenase-2.
  • Diastereo- and enantioselective synthesis of densely functionalized cyclohexanones via double Michael addition of curcumins with nitroalkenes
    作者:Narasimham Ayyagari、Irishi N.N. Namboothiri
    DOI:10.1016/j.tetasy.2012.04.011
    日期:2012.4
    The asymmetric double Michael additions of curcumins to nitroalkenes to afford highly functionalized cyclohexanones have been carried out for the first time. A combination of a dihydrocinchonine-thiourea organocatalyst and K2CO3 was found to be the most effective in obtaining the desired cyclohexanones in good yield, diastereoselectivity and enantioselectivity. (C) 2012 Elsevier Ltd. All rights reserved.
查看更多